News >

New Treatment Indications Boost Survival in Metastatic Hormone-Sensitive Prostate Cancer

Caroline Seymour
Published: Friday, Feb 07, 2020

William Oh, MD

William Oh, MD
Androgen receptor (AR) inhibitors have become staples of treatment alongside docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC), according to William K. Oh, MD, citing several clinical trials as showcasing benefit with this class of agents in this setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication